Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model

Hiroshi Kato, Tomohiro Mizuno, Masashi Mizuno, Akiho Sawai, Yasuhiro Suzuki, Hiroshi Kinashi, Fumiko Nagura, Shoichi Maruyama, Yukihiro Noda, Kiyofumi Yamada, Seiichi Matsuo, Yasuhiko Ito

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. Atrial natriuretic peptide (ANP) was recently reported to ameliorate fibrosis in the heart and experimental renal diseases and vascular thickening after balloon injury. Peritoneal fibrosis is an important complication of long-term peritoneal dialysis, and peritonitis is a factor in its onset. In the present study, we investigated the effects of ANP in a rat peritonitis-induced peritoneal fibrosis model. Methods. As pretreatment, an osmotic pump containing vehicle (saline) or ANP (0.15 or 0.3 μg/min) was inserted through the carotid vein in male Sprague-Dawley rats. ANP or saline was continuously infused using the osmotic pump. Three days after administration of ANP or saline, rats underwent peritoneal scraping in a blind manner and were sacrificed on Day 14. The effects of ANP were evaluated based on peritoneal thickness, immunohistochemistry and real-time polymerase chain reaction. In each experiment, we evaluated messenger RNA (mRNA) expression of the ANP receptor natriuretic peptide receptor A (NPR-A) in the peritoneum after scraping. The effects of ANP were also studied in cultured peritoneal fibroblasts and mesothelial cells. Results. We observed a significant increase in NPR-A mRNA in the peritoneum. Peritoneal thickness increased with time and peaked on Day 14, but ANP significantly reduced peritoneal thickness. Parameters such as number of macrophages and CD-31-positive vessels and expression of type III collagen/transforming growth factor-β/plasminogen activator inhibitor-1 (PAI-1)/connective tissue growth factor (CTGF) were significantly suppressed by ANP. In cultured peritoneal fibroblasts and mesothelial cells, ANP suppressed angiotensin II-induced upregulation of CTGF and PAI-1.Conclusions.Our results suggest that ANP is useful in preventing inflammation-induced peritoneal fibrosis.

Original languageEnglish
Pages (from-to)526-536
Number of pages11
JournalNephrology Dialysis Transplantation
Volume27
Issue number2
DOIs
Publication statusPublished - 02-2012

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model'. Together they form a unique fingerprint.

  • Cite this

    Kato, H., Mizuno, T., Mizuno, M., Sawai, A., Suzuki, Y., Kinashi, H., Nagura, F., Maruyama, S., Noda, Y., Yamada, K., Matsuo, S., & Ito, Y. (2012). Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model. Nephrology Dialysis Transplantation, 27(2), 526-536. https://doi.org/10.1093/ndt/gfr302